The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

The classical understanding of personal autonomy, which still influences medical guidelines, is based on an individualistic framework and is inadequate for ethical mental health care. The goal of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Commissions do not affect our editors' opinions or evaluations. Medical billing software helps doctors and medical offices automate the healthcare billing process. Finding the right computer ...